AgomAb Therapeutics

AgomAb Therapeutics (Ticker: AGMB US) develops treatments for fibrosis, including an oral candidate being developed for Crohn’s disease with fibrostenosis. Its candidate Ontunisertib (AGMB-129) is an oral treatment being developed for Crohn’s disease with fibrostenosis. The company plans to use IPO proceeds to fund continued clinical development of its candidates.

The scheduled listing date on Nasdaq was February 6, 2026. The proposed offering comprises 12,500,000 shares at an indicative price range of $15.00–17.00 per share. At the indicative range midpoint, the base offering would represent $200.00 million in gross proceeds, excluding any unexercised over-allotment. The indicated IPO market capitalization is $779.80 million.

J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen are the lead underwriters.